CVN424
CNS pen. GPR6 GPCR inverse agonist oral QD Ph. II candidate for Parkinson's from 360k cmpd cell-based HTS + opt. J. Pharmacol. Exp. Ther., Apr. 1, 2021 Cerevance / Takeda California, San Diego, US
Molecules of the Month - March 2021
Molecules of the Month
- LSN3318839
- GLPG1972
- APJ compound 14
- encequidar
- S62798 (Servier)
- CVN424
- ABBV-167
- GDC-0310
- "compound 72"
- "compound 20"
- TAK-418
- compound 13 (GSK716)
- RBN-012759
- sisunatovir